Key Highlights
- KOD shares soared 177.96% to $89.92 at Monday's close on September 28, 2026, as the Nasdaq Composite lost 0.92%.
- Kodiak reported positive topline results from its pivotal Phase 3 DAYBREAK study in wet age-related macular degeneration.
- The company said the study met its goal on a topline basis, with detailed data left to its disclosures.
- Kodiak is a clinical-stage biopharmaceutical company focused on retinal and other eye diseases with large patient populations.
Kodiak Sciences (NASDAQ:KOD) closed up 177.96% at $89.92 on Monday, September 28, 2026. The clinical-stage retinal disease company reported positive topline results from its pivotal Phase 3 DAYBREAK study.
Latest Developments
Kodiak reported positive topline results from its pivotal Phase 3 DAYBREAK study, and said the study met its goal on a topline basis. The study evaluated the company's candidates, including its therapy referred to in company materials as Zenkuda alongside KSI-501, in patients with wet age-related macular degeneration.
KOD shares soared at Monday's close, one of the standout gains on the US tape in a session when the major indexes fell.
Financial and Business Position
Kodiak is a clinical-stage biopharmaceutical company focused on retinal and other eye diseases, a therapeutic area with large patient populations and demanding treatment regimens. Specific efficacy statistics, endpoint details and safety data sit in the company's own disclosures.
For a clinical-stage company, a positive pivotal Phase 3 readout is the kind of event that can transform the Investment case in a single trading day, because it materially reduces the binary trial risk that typically overhangs such names.
Stock-Market Context
Major US indexes ended Monday lower and breadth was weak: the S&P 500 dropped 0.77% to 7,683.69, the Nasdaq Composite dropped 0.92% to 26,820.38 and the Dow Jones Industrial Average dropped 0.67% to 51,481.51, with roughly two-thirds of US-listed issues declining.
Treasury yields pushed higher, with the 10-year note above 5.2% for a multi-year high, and oil prices rose as US-Iran talks stalled after a rejected Iranian proposal.
A positive pivotal readout is a milestone rather than an endpoint. Regulatory review, full data disclosure, potential commercialization, competition in the retinal-therapy space and the company's financing position remain relevant considerations.
From Topline Milestone to Full Data
Kodiak closed Monday far above its prior close in a session when the major indexes fell, with the company reporting positive topline Phase 3 results in wet AMD. The next steps are full data disclosure and regulatory review.






Please wait processing your request...